Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 85,947 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1 Clear all
Completed No phase listed Observational Accepts healthy volunteers

Early Onset and Familial Gastric Cancer Registry

NCT00582257
View directory record Official record
Conditions
Gastric Cancer
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Nov 12, 2026, 4:13 AM EST
Terminated Phase 4 Interventional Results available

Cilostazol After Lower Extremity Arterial Revascularization Trial

NCT02374957
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication (Finding)
Interventions
Cilostazol
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Nov 12, 2026, 4:13 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

ERr 731® Formulation Evaluation

NCT05959057
View directory record Official record
Conditions
Menopause
Interventions
ERr 731 - Micro-coated, ERr 731 - Enteric coated
Dietary Supplement
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
35 Years to 64 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Nov 12, 2026, 4:13 AM EST
Completed Phase 2Phase 3 Interventional

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

NCT00223301
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mycophenolate Mofetil (cellcept)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Nov 12, 2026, 4:13 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Community Activation for Prevention (CAPs): A Study of Community Gardening

NCT03089177
View directory record Official record
Conditions
Cancer, Obesity, Lifestyle, Sedentary, Physical Activity, Health Behavior, Chronic Disease, Diet Modification
Interventions
Community Garden Intervention
Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Nov 12, 2026, 4:13 AM EST
Completed Phase 4 Interventional

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

NCT00950677
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Byetta (exenatide), Symlin (pramlintide)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Nov 12, 2026, 4:13 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients

NCT05583877
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes BOOST, Usual Care
Behavioral
Lead sponsor
Daniel Amante
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 12, 2026, 4:13 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

NCT05635357
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, Exemestane/Letrozole
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
16,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Nov 12, 2026, 4:13 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Connecting Youth and Young Adults to Optimize ART Adherence: YouTHrive Efficacy Trial

NCT03149757
View directory record Official record
Conditions
HIV Infections
Interventions
YouTHrive, Information-only Control
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 24 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 12, 2026, 4:13 AM EST
Terminated Phase 1 Interventional

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

NCT01025570
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Bosutinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
San Francisco, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Nov 12, 2026, 4:13 AM EST
Completed Not applicable Interventional Results available

Sweetgoals for Type 1 Diabetes

NCT04646473
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Coaching, Incentives, Sweetgoals app
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
19 Years to 29 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 12, 2026, 4:13 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Ovulation Incidence in Oral Contraceptive Users

NCT03106454
View directory record Official record
Conditions
Contraception, Ovulation
Interventions
Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Nov 12, 2026, 4:13 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Feasibility of Self or Partner-assisted Digital Anal Exam Screening

NCT02384005
View directory record Official record
Conditions
Anus Neoplasms
Interventions
Self-anal exam arm
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
27 Years to 80 Years · Male only
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Nov 12, 2026, 4:13 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

NCT00491894
View directory record Official record
Conditions
Cerebral Palsy, Neurological Conditions, Mental Retardation, Sialorrhea
Interventions
Oral Glycopyrrolate Liquid
Drug
Lead sponsor
Shionogi
Industry
Eligibility
3 Years to 18 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Lakewood, Colorado • Atlanta, Georgia • Bayside, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Nov 12, 2026, 4:13 AM EST
Terminated Phase 1 Interventional

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01076556
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Interventions
Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Nov 12, 2026, 4:13 AM EST
Not listed Not applicable Interventional

Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions

NCT02292056
View directory record Official record
Conditions
Mental Disorders, Contraception, Chemical Teratogen Exposure
Interventions
1-on-1 counseling
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Nov 12, 2026, 4:13 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

NCT00934856
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Pertuzumab, Trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Nov 12, 2026, 4:13 AM EST
Terminated Not applicable Interventional

Remote Ischemic Preconditioning to Prevent Contrast Nephropathy

NCT02674451
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Remote ischemic preconditioning
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Nov 12, 2026, 4:13 AM EST
Active, not recruiting Phase 1 Interventional

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT01375829
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Ixabepilone, Pharmacological Study, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 12, 2026, 4:13 AM EST
Recruiting Not applicable Interventional

Impact of Dog Adoption and Training in Veterans With Post-traumatic Stress Symptoms and/or Other Mental Health Conditions

NCT07542431
View directory record Official record
Conditions
Posttraumatic Stress Symptoms, Mental Health Conditions
Interventions
Dog training
Other
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 12, 2026, 4:13 AM EST
Completed Phase 2 Interventional

Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

NCT00361153
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Colesevelam hydrochloride, placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2008 · Synced Nov 12, 2026, 4:13 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

NCT02038153
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission
Interventions
Laboratory Biomarker Analysis, Lenalidomide
Other · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
60 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
The Bronx, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Nov 12, 2026, 4:13 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)

NCT06688045
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib, Itraconazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Nov 12, 2026, 4:13 AM EST
Terminated Phase 3 Interventional Results available

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

NCT03626545
View directory record Official record
Conditions
Non-Small-Cell Lung
Interventions
Canakinumab, Docetaxel, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Nov 12, 2026, 4:13 AM EST